Khong T - Search Results

1

Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma.

Mithraprabhu S, Kalff A, Gartlan KH, Savvidou I, Khong T, Ramachandran M, Cooke RE, Bowen K, Hill GR, Reynolds J, Spencer A. Mithraprabhu S, et al. Among authors: khong t. Br J Haematol. 2021 Apr;193(1):160-170. doi: 10.1111/bjh.17080. Epub 2020 Sep 18. Br J Haematol. 2021. PMID: 32945549 Free PMC article. Clinical Trial.

2

PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells.

Sharkey J, Khong T, Spencer A. Sharkey J, et al. Among authors: khong t. Blood. 2007 Feb 15;109(4):1712-9. doi: 10.1182/blood-2006-05-014092. Epub 2006 Oct 10. Blood. 2007. PMID: 17032922 Free article.

3

The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma.

Khong T, Sharkey J, Spencer A. Khong T, et al. Haematologica. 2008 Jun;93(6):860-9. doi: 10.3324/haematol.12261. Epub 2008 Apr 28. Haematologica. 2008. PMID: 18443271 Free article.

4

CYT997 causes apoptosis in human multiple myeloma.

Monaghan K, Khong T, Smith G, Spencer A. Monaghan K, et al. Among authors: khong t. Invest New Drugs. 2011 Apr;29(2):232-8. doi: 10.1007/s10637-009-9350-5. Epub 2009 Nov 12. Invest New Drugs. 2011. PMID: 19907921

5

Deactylase inhibition in myeloproliferative neoplasms.

Mithraprabhu S, Grigoriadis G, Khong T, Spencer A. Mithraprabhu S, et al. Among authors: khong t. Invest New Drugs. 2010 Dec;28 Suppl 1(Suppl 1):S50-7. doi: 10.1007/s10637-010-9590-4. Epub 2010 Dec 3. Invest New Drugs. 2010. PMID: 21127942 Free PMC article. Review.

6

The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.

Monaghan KA, Khong T, Burns CJ, Spencer A. Monaghan KA, et al. Among authors: khong t. Leukemia. 2011 Dec;25(12):1891-9. doi: 10.1038/leu.2011.175. Epub 2011 Jul 26. Leukemia. 2011. PMID: 21788946

7

Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.

Khong T, Spencer A. Khong T, et al. Mol Cancer Ther. 2011 Oct;10(10):1909-17. doi: 10.1158/1535-7163.MCT-11-0174. Epub 2011 Aug 22. Mol Cancer Ther. 2011. PMID: 21859842

8

Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC.

Mithraprabhu S, Khong T, Jones SS, Spencer A. Mithraprabhu S, et al. Among authors: khong t. Br J Haematol. 2013 Aug;162(4):559-62. doi: 10.1111/bjh.12388. Epub 2013 May 21. Br J Haematol. 2013. PMID: 23692150 Free article. No abstract available.

9

Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton.

Mithraprabhu S, Khong T, Spencer A. Mithraprabhu S, et al. Among authors: khong t. Cell Death Dis. 2014 Mar 20;5(3):e1134. doi: 10.1038/cddis.2014.98. Cell Death Dis. 2014. PMID: 24651437 Free PMC article.

10

A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia.

Kalff A, Khong T, Wall M, Gorniak M, Mithraprabhu S, Campbell LJ, Spencer A. Kalff A, et al. Among authors: khong t. Haematologica. 2015 Feb;100(2):e60-2. doi: 10.3324/haematol.2014.111385. Epub 2014 Nov 7. Haematologica. 2015. PMID: 25381133 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

293 results

Search Page